How Archer Materials Is Pioneering Carbon Qubits and Silicon Biochips in Q2 FY26

Quantum Computing Advances

Archer Materials has reported meaningful progress in its 12CQ project, which focuses on developing carbon-based qubits for quantum computing. The company has enhanced its quantum state readout capabilities, a critical step toward demonstrating functional qubits. Notably, Archer successfully synthesised its carbon qubit material on a one-inch silicon wafer and demonstrated electron spin lifetimes exceeding 0.4 microseconds at room temperature, positioning its technology competitively against other quantum platforms.

These advancements include refining gating and single-electron transistor architectures, and achieving electrical gating within quantum devices using carbon nano-onions. Such technical milestones not only improve manufacturability but also support scalability, essential for commercial quantum devices.

Strategic Collaborations Expand Reach

During the quarter, Archer signed a collaboration agreement with Emergence Quantum, a leader in quantum technology, to explore graphene and carbon-based technologies for next-generation quantum and electronic devices. Additionally, Archer partnered with CSIRO to develop quantum machine learning models aimed at enhancing financial fraud detection, with potential applications beyond finance.

These partnerships underscore Archer’s strategy to leverage external expertise and broaden the commercial potential of its quantum technologies across computing, sensing, and machine learning domains.

Biochip Program Hits Clinical Milestone

On the medical diagnostics front, Archer’s Biochip team, in collaboration with IMEC, demonstrated that its silicon-based potassium testing device meets clinical accuracy standards. Transitioning the Biochip to a silicon platform is a strategic move that could reduce costs, de-risk supply chains, and accelerate regulatory approval processes.

The silicon Biochip also offers faster readout times compared to previous graphene-based devices, enhancing its suitability for point-of-care testing, particularly for patients with chronic kidney disease who require regular potassium monitoring.

Financial and Corporate Updates

Archer closed the quarter with a healthy cash balance of $10.3 million, excluding a $2.1 million R&D tax rebate received shortly after quarter-end. The company reported no debt, reflecting a solid financial footing to support ongoing development activities.

Governance changes included the appointment of Andrew Just as a Non-Executive Director. With three decades of global experience in health industry growth and technology scaling, Mr Just’s expertise is expected to bolster Archer’s Biochip commercialization efforts.

Looking Ahead

Archer’s progress across its quantum and medical diagnostic platforms, combined with strategic partnerships and financial stability, positions the company well as it moves toward key commercialisation milestones. The upcoming investor webinar will provide further insights into these developments and the company’s roadmap.